Search / Trial NCT00001874

Technical Evaluation of Cardiovascular Magnetic Resonance Imaging and Spectroscopy

Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · Nov 3, 1999

Apply for Trial

Trial Information

Current as of April 29, 2024

Completed

Keywords

Imaging Spectroscopy Mri Cardiovascular Technical Development Safety Gadolinium Heart Toxicity Adverse Events Normal Volunteer

Description

Technical evaluation of magnetic resonance imaging and spectroscopy will be performed on normal volunteers. These studies will be conducted in the NIH MRI systems located in Suburban Hospital in Bethesda, Maryland. These studies may involve the intravenous administration of commercially available MR contrast media and exercise. The results will be used to evaluate the performance of various pulse sequences, gradient coils, and RF coils on human subjects and will provide essential ground work for specific patient protocols.

Gender

All

Eligibility criteria

  • INCLUSION CRITERIA:
  • Any normal volunteer above the age 18 who is capable of giving informed consent will be included.
  • EXCLUSION CRITERIA:
  • A subject will be excluded if he/she has a contradiction to MR scanning.
  • Brain aneurysm clip
  • Implanted neural stimulator
  • Implanted cardiac pacemaker implanted defibrillator
  • Cochlear implant
  • Ocular foreign body (e.g. metal shavings)
  • Insulin pump
  • Pregnant women (when uncertain, subjects will undergo urine or blood testing).
  • Kidney
  • Paralyzed hemidiaphragm
  • Morbid obesity
  • Claustrophobia
  • Any condition in the PI's judgement which present unncessary risk
  • EXCLUSION CRITERIA FOR GADOLINIUM ENHANCED STUDIES:
  • Lactating women
  • Subjects with hemoglobinopathies
  • Asthma
  • Renal or hepatic disease
  • Subjects will be excluded if it is deemed that they have a condition that would preclude their use for technical development (e.g. paralyzed hemidiaphragm, morbid obesity, claustrophobia etc.) or present unnecessary risk (e.g. pregnancy, surgery of uncertain type, etc.).
  • Lactating women and subjects with hemoglobinopathies, asthma, or renal or hepatic disease will be excluded from studies involving the adminstration of contrast agents.

Attachments

readout_NCT00001874_2024-04-29.pdf

4.5 MB

NCT00001874_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0